Agios Pharmaceuticals 향후 성장

Future 기준 점검 2/6

Agios Pharmaceuticals 의 수익은 연간 20.9% 감소할 것으로 예상되는 반면, 연간 수익은 55% 로 증가할 것으로 예상됩니다. EPS는 연간 22.1% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 -28.8% 로 예상됩니다.

핵심 정보

-20.9%

이익 성장률

-22.11%

EPS 성장률

Biotechs 이익 성장	25.3%
매출 성장률	55.0%
향후 자기자본이익률	-28.77%
애널리스트 커버리지	Good
마지막 업데이트	10 Sep 2025

최근 향후 성장 업데이트

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 04

Recent updates

Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated

Sep 04

Why Agios Pharmaceuticals' (NASDAQ:AGIO) Earnings Are Weaker Than They Seem

Feb 20

Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)

Feb 14

Mitapivat May Launch In 2025 For Blood Disorders But Faces Regulatory And Competition Challenges

Feb 09 Mitapivat's launch in thalassemia and sickle cell markets promises revenue growth from new opportunities, leveraging positive Phase III data for adoption.

Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision

Jan 14

Agios Pharmaceuticals: A Long Overdue Follow Up

Dec 03

We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate

Sep 26

Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment

Aug 27

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 04

Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

Jun 12

Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth

Jun 02

Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Feb 17

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Jan 16

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%

Nov 09

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Sep 26

Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

May 08

We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely

Feb 06

Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans

Oct 18

Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU

Sep 16

Agios adds more than 13% after Novo deal to acquire rival Forma

Sep 01

이익 및 매출 성장 예측

NasdaqGS:AGIO - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	272	-315	-251	N/A	7
12/31/2026	108	-442	-395	-312	8
12/31/2025	44	-431	-395	-331	8
6/30/2025	41	650	-409	-406	N/A
3/31/2025	37	666	-404	-401	N/A
12/31/2024	36	674	-392	-390	N/A
9/30/2024	33	674	-330	-329	N/A
6/30/2024	31	-365	-325	-307	N/A
3/31/2024	29	-353	-319	-301	N/A
12/31/2023	27	-352	-315	-296	N/A
9/30/2023	24	-220	-308	-290	N/A
6/30/2023	20	-210	-300	-299	N/A
3/31/2023	19	-218	-309	-307	N/A
12/31/2022	14	-232	-314	-309	N/A
9/30/2022	10	-367	-337	-327	N/A
6/30/2022	6	-369	-350	-341	N/A
3/31/2022	1	-360	-392	-384	N/A
12/31/2021	N/A	-357	-413	-407	N/A
9/30/2021	N/A	-342	-374	-373	N/A
6/30/2021	N/A	-337	-363	-356	N/A
3/31/2021	N/A	-336	-317	-306	N/A
12/31/2020	N/A	-329	-305	-291	N/A
9/30/2020	35	-347	-355	-335	N/A
6/30/2020	61	-374	-370	-352	N/A
3/31/2020	88	-402	-387	-373	N/A
12/31/2019	N/A	-301	-383	-371	N/A
9/30/2019	112	-401	-358	-351	N/A
6/30/2019	102	-389	-337	-329	N/A
3/31/2019	116	-348	N/A	-309	N/A
12/31/2018	94	-346	N/A	-304	N/A
9/30/2018	74	-343	N/A	-305	N/A
6/30/2018	70	-325	N/A	-319	N/A
3/31/2018	41	-339	N/A	-310	N/A
12/31/2017	43	-315	N/A	-285	N/A
9/30/2017	56	-283	N/A	-262	N/A
6/30/2017	53	-269	N/A	-233	N/A
3/31/2017	49	-241	N/A	-17	N/A
12/31/2016	70	-198	N/A	39	N/A
9/30/2016	53	-183	N/A	59	N/A
6/30/2016	50	-160	N/A	83	N/A
3/31/2016	56	-136	N/A	-70	N/A
12/31/2015	59	-118	N/A	-77	N/A
9/30/2015	68	-104	N/A	-54	N/A
6/30/2015	96	-60	N/A	-53	N/A
3/31/2015	91	-46	N/A	-58	N/A
12/31/2014	65	-54	N/A	-59	N/A

애널리스트 향후 성장 전망

수입 대 저축률: AGIO 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -20.9%).

수익 vs 시장: AGIO 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -20.9%).

고성장 수익: AGIO 의 수익은 향후 3년간 감소할 것으로 예상됩니다.

수익 대 시장: AGIO 의 수익(연간 55%)이 US 시장(연간 9.8%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: AGIO 의 수익(연간 55%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: AGIO는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/10/03 14:53
종가	2025/10/03 00:00
수익	2025/06/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Agios Pharmaceuticals, Inc.는 31명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Peter Lawson	Barclays
George Farmer	BMO Capital Markets Equity Research
Alec Stranahan	BofA Global Research

Agios Pharmaceuticals 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Consensus revenue estimates fall by 43%

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Forecast to breakeven in 2024

Consensus EPS estimates upgraded to US$3.16 loss

Price target increased by 13% to US$46.00

Consensus revenue estimates decrease by 33%, EPS upgraded

Recent updates

Insider recently sold US$315k worth of stock

Agios Pharmaceuticals, Inc. Provides Update on U.S. PDUFA Goal Date for PYRUKYND (mitapivat) in Thalassemia

Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated

CEO & Director notifies of intention to sell stock

Agios Pharmaceuticals, Inc.'s PYRUKYND®? (Mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

New major risk - Earnings quality

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider notifies of intention to sell stock

Agios Pharmaceuticals, Inc. Appoints Jay Backstrom to Board of Directors and Science and Technology Committee

CEO & Director notifies of intention to sell stock

New major risk - Earnings quality

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2025

Agios Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 01, 2025

Chair of the Board of Directors notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

High number of new directors

Why Agios Pharmaceuticals' (NASDAQ:AGIO) Earnings Are Weaker Than They Seem

Consensus revenue estimates fall by 43%

Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Agios Pharmaceuticals, Inc. Announces Resignation of David P. Schenkein, M.D from Board of Directors and Member of the Science and Technology Committee, Effective February 28, 2025

Mitapivat May Launch In 2025 For Blood Disorders But Faces Regulatory And Competition Challenges

Agios Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 13, 2025

Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision

FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 17%

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

Agios Pharmaceuticals: A Long Overdue Follow Up

Insider notifies of intention to sell stock

Investor sentiment improves as stock rises 24%

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Agios Pharmaceuticals, Inc. Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

New major risk - Revenue and earnings growth

We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate

Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment

CEO & Director notifies of intention to sell stock

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Agios Pharmaceuticals, Inc. Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

New minor risk - Profitability

Agios Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

Forecast to breakeven in 2024

Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

CEO & Director notifies of intention to sell stock

New minor risk - Share price stability

Agios Pharmaceuticals, Inc. Announces Phase 3 Energize-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth

Consensus EPS estimates upgraded to US$3.16 loss

Price target increased by 13% to US$46.00

Consensus revenue estimates decrease by 33%, EPS upgraded

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Shareholder dilution

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Chair of the Board of Directors exercised options and sold US$215k worth of stock

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 46%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Consensus revenue estimates fall by 43%

Agios Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Chair of the Board of Directors exercised options and sold US$232k worth of stock

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

CEO & Director exercised options and sold US$277k worth of stock

Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio